Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 4/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8035323 | 0.90 | HRH3 (0.61) | HRH3MAOBMAOASLC6A4PDE4D | |
| SCHEMBL18033522 | 0.85 | HRH3 (0.43) | HRH3MAOBMAOASLC6A4MAP3K5 | |
| SCHEMBL29557863 | 0.83 | HRH3 (0.51) | HRH3MAOBMAOASLC6A4PDE4D | |
| SCHEMBL29520625 | 0.83 | HRH3 (0.51) | HRH3MAOBMAOASLC6A4PDE4D | |
| SCHEMBL26922403 | 0.83 | HRH3 (0.51) | HRH3MAOBMAOASLC6A4PDE4D | |
| SCHEMBL24620314 | 0.83 | HRH3 (0.51) | HRH3MAOBMAOASLC6A4PDE4D | |
| SCHEMBL29516213 | 0.83 | HRH3 (0.51) | HRH3MAOBMAOASLC6A4PDE4D | |
| SCHEMBL2202209 | 0.83 | HRH3 (0.51) | HRH3MAOBMAOASLC6A4PDE4D | |
| SCHEMBL12938115 | 0.79 | HRH3 (0.46) | HRH3MAOBMAOASLC6A4PDE4D | |
| SCHEMBL24746023 | 0.79 | MAOA (0.80) | MAOBMAOASLC6A4PDE4DCA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8906913-B2 | Azabicyclohexanes | PANACEA BIOTEC LIMITED (IN) | 2014-12-09 | — | — | US | disclosed |
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | PANACEA BIOTEC LTD. (IN) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | CYP3A43, UGT1A1, CYP3A4 | HRH3 2777/4885MAOB 227/4885MAOA 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.